Skip to main content
. 2017 Apr 21;32(9):1860–1869. doi: 10.1002/jbmr.3138

Figure 4.

Figure 4

OX14 prevents osteolytic disease in JJN3‐bearing NSG mice. (A) Representative longitudinal and transverse µCT images of tibias from NSG mice, at the end stage of disease, injected with vehicle (naive) (i), 1 × 106 JJN3 cells (JJN3) (ii) or JJN3 cells, and treated with ZOL (JJN3+ZOL) (iii) or OX14 (JJN3+OX14) (iv). (B) μCT analysis of the number of cortical bone lesions. (C) μCT analysis of BV/TV (%). Data are presented as mean ± SE and significance from the nontumor control group (naive) is indicated, where *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.